Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
5.64
+0.39 (7.43%)
At close: Jul 2, 2026, 4:00 PM EDT
5.60
-0.04 (-0.71%)
After-hours: Jul 2, 2026, 7:54 PM EDT
Precigen Employees
Precigen had 160 employees as of December 31, 2025. The number of employees increased by 17 or 11.89% compared to the previous year.
Employees
160
Change (1Y)
17
Growth (1Y)
11.89%
Revenue / Employee
$197,469
Profits / Employee
-$2,396,363
Market Cap
2.01B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 160 | 17 | 11.89% | 160 | 0 |
| Dec 31, 2024 | 143 | -59 | -29.21% | 143 | 0 |
| Dec 31, 2023 | 202 | -7 | -3.35% | 202 | 0 |
| Dec 31, 2022 | 209 | -302 | -59.10% | 209 | 0 |
| Dec 31, 2021 | 511 | 34 | 7.13% | 456 | 55 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| ADMA Biologics | 647 |
| Recursion Pharmaceuticals | 600 |
| Lakefront Biotherapeutics NV | 558 |
| Nuvation Bio | 307 |
| Monte Rosa Therapeutics | 187 |
| Stoke Therapeutics | 170 |
| Absci | 140 |
PGEN News
- 16 days ago - Precigen Transcript: AGM 2026 - Transcripts
- 19 days ago - Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging - Accesswire
- 23 days ago - Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices - PRNewsWire
- 26 days ago - Precigen Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Precigen presents long-term follow-up data from study of Papzimeos - TheFly
- 4 weeks ago - Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years - PRNewsWire
- 5 weeks ago - Precigen price target raised to $14 from $11 at H.C. Wainwright - TheFly
- 5 weeks ago - Precigen receives orphan drug exclusivity for papzimeos in the U.S. - TheFly